Ophthalmic compositions comprising povidone-iodine
View Patent ↗A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.
1. A composition comprising a mixture of
a) povidone-iodine at a concentration between 0.1% and 2.5% by weight, and
b) a steroid at a concentration of between 0.05 and 2% by weight, wherein the steroid is dexamethasone, and wherein, after a period of one month after mixing the steroid and povidone-iodine to form the composition, the steroid concentration is at least 90% by weight of the steroid starting concentration, and wherein said composition is in the form of a suspension.
2. The composition of claim 1 , wherein said povidone-iodine is between 0.5% and 2% by weight.
3. The composition of claim 1 , wherein said composition further comprises an antimicrobial preservative.
4. The composition of claim 3 , wherein said antimicrobial preservative is selected from the group consisting of benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propylparaben, phenyl ethyl alcohol, ethylenediaminetetraacetic acid, sorbic acid, polyquarternium 1, and a combination thereof.
5. The composition of claim 4 , wherein said co-solvent/surfactant is ethylenediaminetetraacetic acid.
6. The composition of claim 5 , wherein said antimicrobial preservative is at a concentration of about 0.001% to 1.0% by weight in said composition.
7. The composition of claim 1 , wherein said composition further comprises a co-solvent/surfactant.
8. The composition of claim 7 , wherein said co-solvent/surfactant is selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80, Pluronic F-68, Pluronic F-84, Pluronic P-103, cyclodextrin, tyloxapol, and a combination thereof.
9. The composition of claim 8 , wherein said co-solvent/surfactant is tyloxapol.
10. The composition of claim 9 , wherein said co-solvent/surfactant is at a concentration of about 0.01% to 2% by weight in said composition.
11. The composition of claim 1 , wherein said composition further comprises a viscosity increasing agent.
12. The composition of claim 11 , wherein said viscosity increasing agent is selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, and a combination thereof.
13. The composition of claim 12 , wherein said viscosity increasing agent is hydroxyethyl cellulose.
14. The composition of claim 13 , wherein said viscosity increasing agent is at a concentration of about 0.01% to 2% by weight in said composition.
15. The composition of claim 1 , comprising:
0.5 to 2% (w/w) povidone-iodine;
0.05 to 2% (w/w) steroid;
0.005% to 0.02% (w/w) ethylenediaminetetraacetic acid;
0.01 to 0.5% (w/w) sodium chloride;
0.02 to 0.1% (w/w) tyloxapol;
0.5% to 2% (w/w) sodium sulfate;
0.01 to 0.5% (w/w) sodium chloride;
and 0.1 to 0.5% (w/w) hydroxyethylcellulose.
16. The composition of claim 1 , comprising:
0.5 to 2% (w/w) povidone-iodine;
0.05 to 2% (w/w) steroid;
0.01% (w/w) ethylenediaminetetraacetic acid disodium salt;
0.01 to 0.5% (w/w) sodium chloride;
0.05% (w/w) tyloxapol;
1.2% (w/w) sodium sulfate;
0.01 to 0.5% (w/w) sodium chloride;
and 0.25% (w/w) hydroxyethylcellulose.
17. The composition of claim 1 , comprising:
0.5 to 2% (w/w) povidone-iodine;
0.1% (w/w) steroid;
0.01% (w/w) ethylenediaminetetraacetic acid disodium salt;
0.01 to 0.5% (w/w) sodium chloride;
0.05% (w/w) tyloxapol;
1.2% (w/w) sodium sulfate;
0.01 to 0.5% (w/w) sodium chloride;
and 0.25% (w/w) hydroxyethylcellulose.
18. A composition comprising a mixture of
a) povidone-iodine at a concentration between 0.1% and 2.5% by weight, and
b) a steroid at a concentration of between 0.05 and 2% by weight, wherein the steroid is dexamethasone, and wherein, after a period of one month after mixing the steroid and povidone-iodine to form the composition, the povidone-iodine concentration is at least 90% by weight of the povidone-iodine starting concentration, and wherein said composition is in the form of a suspension.
19. The composition of claim 18 , wherein said povidone-iodine is between 0.5% and 2% by weight.
20. The composition of claim 18 , wherein said composition further comprises an antimicrobial preservative.
21. The composition of claim 20 , wherein said antimicrobial preservative is selected from the group consisting of benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propylparaben, phenyl ethyl alcohol, ethylenediaminetetraacetic acid, sorbic acid, polyquarternium 1, and a combination thereof.
22. The composition of claim 21 , wherein said antimicrobial preservative is at a concentration of about 0.001% to 1.0% by weight in said composition.
23. The composition of claim 22 , wherein said composition further comprises a co-solvent/surfactant.
24. The composition of claim 23 , wherein said co-solvent/surfactant is selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80, Pluronic F-68, Pluronic F-84, Pluronic P-103, cyclodextrin, tyloxapol, and a combination thereof.
25. The composition of claim 24 , wherein said co-solvent/surfactant is tyloxapol.
26. The composition of claim 25 , wherein said co-solvent/surfactant is at a concentration of about 0.01% to 2% by weight in said composition.
27. The composition of claim 17 , wherein said composition further comprises a viscosity increasing agent.
28. The composition of claim 27 , wherein said viscosity increasing agent is selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, and a combination thereof.
29. The composition of claim 28 , wherein said viscosity increasing agent is hydroxyethyl cellulose.
30. The composition of claim 29 , wherein said viscosity increasing agent is at a concentration of about 0.01% to 2% by weight in said composition.
31. The composition of claim 17 , comprising:
0.5 to 2% (w/w) povidone-iodine;
0.05 to 2% (w/w) steroid;
0.005% to 0.02% (w/w) ethylenediaminetetraacetic acid;
0.01 to 0.5% (w/w) sodium chloride;
0.02 to 0.1% (w/w) tyloxapol;
0.5% to 2% (w/w) sodium sulfate;
0.01 to 0.5% (w/w) sodium chloride;
and 0.1 to 0.5% (w/w) hydroxyethylcellulose.
32. The composition of claim 17 , comprising:
0.5 to 2% (w/w) povidone-iodine;
0.05 to 2% (w/w) steroid;
0.01% (w/w) ethylenediaminetetraacetic acid disodium salt;
0.01 to 0.5% (w/w) sodium chloride;
0.05% (w/w) tyloxapol;
1.2% (w/w) sodium sulfate;
0.01 to 0.5% (w/w) sodium chloride;
and 0.25% (w/w) hydroxyethylcellulose.
33. The composition of claim 17 , comprising:
0.5 to 2% (w/w) povidone-iodine;
0.1% (w/w) steroid;
0.01% (w/w) ethylenediaminetetraacetic acid disodium salt;
0.01 to 0.5% (w/w) sodium chloride;
0.05% (w/w) tyloxapol;
1.2% (w/w) sodium sulfate;
0.01 to 0.5% (w/w) sodium chloride;
and 0.25% (w/w) hydroxyethylcellulose.